NCT00896168View on ClinicalTrials.gov

An Efficacy and Safety Study of Infliximab in Participants With Rheumatoid Arthritis

PHASE4CompletedINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

Infliximab

Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.

DRUG

Methotrexate

MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.

All Listed Sponsors
lead

Xian-Janssen Pharmaceutical Ltd.

INDUSTRY

NCT00896168 - An Efficacy and Safety Study of Infliximab in Participants With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter